221 related articles for article (PubMed ID: 26292580)
1. Structural insights into the interactions of phorbol ester and bryostatin complexed with protein kinase C: a comparative molecular dynamics simulation study.
Thangsunan P; Tateing S; Hannongbua S; Suree N
J Biomol Struct Dyn; 2016 Jul; 34(7):1561-75. PubMed ID: 26292580
[TBL] [Abstract][Full Text] [Related]
2. Molecular dynamics simulations reveal ligand-controlled positioning of a peripheral protein complex in membranes.
Ryckbosch SM; Wender PA; Pande VS
Nat Commun; 2017 Feb; 8(1):6. PubMed ID: 28232750
[TBL] [Abstract][Full Text] [Related]
3. Neristatin 1 provides critical insight into bryostatin 1 structure-function relationships.
Kedei N; Kraft MB; Keck GE; Herald CL; Melody N; Pettit GR; Blumberg PM
J Nat Prod; 2015 Apr; 78(4):896-900. PubMed ID: 25808573
[TBL] [Abstract][Full Text] [Related]
4. Ligand structure-activity requirements and phospholipid dependence for the binding of phorbol esters to protein kinase D.
Wang QJ; Fang TW; Yang D; Lewin NE; Van Lint J; Marquez VE; Blumberg PM
Mol Pharmacol; 2003 Dec; 64(6):1342-8. PubMed ID: 14645664
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of the cys2 activator-binding domain of protein kinase C delta in complex with phorbol ester.
Zhang G; Kazanietz MG; Blumberg PM; Hurley JH
Cell; 1995 Jun; 81(6):917-24. PubMed ID: 7781068
[TBL] [Abstract][Full Text] [Related]
6. Toward a biorelevant structure of protein kinase C bound modulators: design, synthesis, and evaluation of labeled bryostatin analogues for analysis with rotational echo double resonance NMR spectroscopy.
Loy BA; Lesser AB; Staveness D; Billingsley KL; Cegelski L; Wender PA
J Am Chem Soc; 2015 Mar; 137(10):3678-85. PubMed ID: 25710634
[TBL] [Abstract][Full Text] [Related]
7. Binding of [26-3H]bryostatin 1 and analogs to calcium-dependent and calcium-independent protein kinase C isozymes.
Kazanietz MG; Lewin NE; Gao F; Pettit GR; Blumberg PM
Mol Pharmacol; 1994 Aug; 46(2):374-9. PubMed ID: 8078499
[TBL] [Abstract][Full Text] [Related]
8. Structural basis of binding of high-affinity ligands to protein kinase C: prediction of the binding modes through a new molecular dynamics method and evaluation by site-directed mutagenesis.
Pak Y; Enyedy IJ; Varady J; Kung JW; Lorenzo PS; Blumberg PM; Wang S
J Med Chem; 2001 May; 44(11):1690-701. PubMed ID: 11356104
[TBL] [Abstract][Full Text] [Related]
9. Molecular dynamics simulation studies on binding of activator and inhibitor to Munc13-1 C1 in the presence of membrane.
You Y; Das J
J Biomol Struct Dyn; 2022; 40(24):14160-14175. PubMed ID: 34779746
[TBL] [Abstract][Full Text] [Related]
10. Modeling studies on the structural determinants for the DAG/phorbol ester binding to C1 domain.
Rahman GM; Das J
J Biomol Struct Dyn; 2015; 33(1):219-32. PubMed ID: 24666138
[TBL] [Abstract][Full Text] [Related]
11. Molecular modeling and site-directed mutagenesis studies of a phorbol ester-binding site in protein kinase C.
Wang S; Kazanietz MG; Blumberg PM; Marquez VE; Milne GW
J Med Chem; 1996 Jun; 39(13):2541-53. PubMed ID: 8691452
[TBL] [Abstract][Full Text] [Related]
12. Structural basis of RasGRP binding to high-affinity PKC ligands.
Rong SB; Enyedy IJ; Qiao L; Zhao L; Ma D; Pearce LL; Lorenzo PS; Stone JC; Blumberg PM; Wang S; Kozikowski AP
J Med Chem; 2002 Feb; 45(4):853-60. PubMed ID: 11831896
[TBL] [Abstract][Full Text] [Related]
13. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.
Szallasi Z; Du L; Levine R; Lewin NE; Nguyen PN; Williams MD; Pettit GR; Blumberg PM
Cancer Res; 1996 May; 56(9):2105-11. PubMed ID: 8616857
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and Biological Evaluation of Fluorescent Bryostatin Analogues.
Cummins TJ; Kedei N; Czikora A; Lewin NE; Kirk S; Petersen ME; McGowan KM; Chen JQ; Luo X; Johnson RC; Ravichandran S; Blumberg PM; Keck GE
Chembiochem; 2018 Apr; 19(8):877-889. PubMed ID: 29424951
[TBL] [Abstract][Full Text] [Related]
15. Comparison of transcriptional response to phorbol ester, bryostatin 1, and bryostatin analogs in LNCaP and U937 cancer cell lines provides insight into their differential mechanism of action.
Kedei N; Telek A; Michalowski AM; Kraft MB; Li W; Poudel YB; Rudra A; Petersen ME; Keck GE; Blumberg PM
Biochem Pharmacol; 2013 Feb; 85(3):313-24. PubMed ID: 23146662
[TBL] [Abstract][Full Text] [Related]
16. Binding of [3H]bryostatin 4 to protein kinase C.
Lewin NE; Dell'Aquila ML; Pettit GR; Blumberg PM; Warren BS
Biochem Pharmacol; 1992 May; 43(9):2007-14. PubMed ID: 1596288
[TBL] [Abstract][Full Text] [Related]
17. Differential selectivity of ligands for the C1a and C1b phorbol ester binding domains of protein kinase Cdelta: possible correlation with tumor-promoting activity.
Bögi K; Lorenzo PS; Szállási Z; Acs P; Wagner GS; Blumberg PM
Cancer Res; 1998 Apr; 58(7):1423-8. PubMed ID: 9537243
[TBL] [Abstract][Full Text] [Related]
18. Bryostatin 1 protects protein kinase C-delta from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation.
Szallasi Z; Denning MF; Smith CB; Dlugosz AA; Yuspa SH; Pettit GR; Blumberg PM
Mol Pharmacol; 1994 Nov; 46(5):840-50. PubMed ID: 7969070
[TBL] [Abstract][Full Text] [Related]
19. Partial parallelism and partial blockade by bryostatin 1 of effects of phorbol ester tumor promoters on primary mouse epidermal cells.
Sako T; Yuspa SH; Herald CL; Pettit GR; Blumberg PM
Cancer Res; 1987 Oct; 47(20):5445-50. PubMed ID: 2888531
[TBL] [Abstract][Full Text] [Related]
20. Bryostatin 1 inhibits phorbol ester-induced apoptosis in prostate cancer cells by differentially modulating protein kinase C (PKC) delta translocation and preventing PKCdelta-mediated release of tumor necrosis factor-alpha.
von Burstin VA; Xiao L; Kazanietz MG
Mol Pharmacol; 2010 Sep; 78(3):325-32. PubMed ID: 20516369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
